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MIFS was originally described as acral MIFS (Meis-
Kindblom and Kindblom, 1998). 
Note 
MIFS is an intermediate malignant soft tissue tumor 
usually located in the subcutaneous tissue of distal 
extremities (Kindblom et al., 2002).  
Distant metastases are rare but the tumor has a 
propensity for multiple local recurrences. An identical 
t(1;10)(p22;q24) has been found in MIFS and 
hemosiderotic fibrolipomatous tumor (HFLT) (Hallor 
et al., 2009; Antonescu et al., 2011). HFLT is an 
intermediate malignant tumor of uncertain 
differentiation, morphologically distinct from MIFS.  
In similarity with MIFS, HFLT has a predilection for 
superficial soft tissue of distal extremities and present 
frequent local recurrences.  
Despite their usually distinct morphology, there are 
tumors with mixed HFLT/MIFS histology (Elco et al., 
2010).  
These tumors also show a t(1;10) and suggest that there
are either different morphological variants or different 
levels of tumor progression of a sole biological entity 
(Antonescu et al., 2011). 
Classification 
Note 
MIFS is an intermediate malignant 





Clinics and pathology 
Disease 
Myxoinflammatory fibroblastic sarcoma (MIFS) 
Phenotype / cell stem origin 
The origin of the tumor cells is unknown. Their 
fibroblastic/myofibroblastic differentiation indicates 




MIFS is a rare soft tissue tumor which primarily affects 
adults without any gender predilection. 
Clinics 
MIFS is an intermediate malignant tumor that usually 
presents as a slowly-growing, poorly-delineated mass 
of the superficial soft tissue of distal extremities 
(Kindblom et al., 2002). It is sometimes associated with 
pain and decreased mobility. In many cases the growth 
has been noted for a relatively long period of time 
before diagnosis. MIFS may be confused with 
inflammatory or post-traumatic lesions, benign or other 
malignant soft tissue tumors. Local recurrences are 
common but distant metastases are very rare. 
Pathology 
MIFS show a poorly delineated, multinodular growth 
pattern with alternating myxoid and cellular areas 
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inflammatory infiltrate that may obscure the neoplastic 
cells and cause misdiagnoses of a reactive or 
inflammatory process. Tumor cells, including large 
polygonal and bizarre ganglion-like cells with 
prominent inclusion-like nucleoli and variably sized, 
multivacuolated lipoblast-like cells, may be scattered 
singly or form coherent clusters. 
Treatment 
The treatment for MIFS is surgical excision. 
Prognosis 
Local recurrences are common and their incidence may 
depend on primary surgical treatment; multiple loca 
recurrences may require eventual amputation 
(Kindblom et al., 2002). Distant metastases are, 
however, exceedingly rare. 
Genetics 
Note 
MIFS, HFLT and tumors with mixed MIFS/HFLT 
histology share the same genetic aberrations; t(1;10) 
and amplification of a region in proximal chromosome 
arm 3p (Antonescu et al., 2011). 
Cytogenetics 
Cytogenetics Morphological 
The majority of cytogenetically analyzed MIFS present 
a t(1;10)(p22;q24), or variants thereof (Mitelman 
Database of Chromosome Aberrations in Cancer 2012).  
Ring and/or giant marker chromosomes as well as 
aberrations involving chromosome 3 are also associated 
with this disease. 
Cytogenetics Molecular 
Fluorescence in situ hybridization analyses, using 
probes flanking the genes TGFBR3 in chromosome 1 
and MGEA5 in chromosome 10, can be used as a 
diagnostic molecular test for MIFS and HFLT 
(Antonescu et al., 2011).  
Amplification of material from chromosome arm 3p 
can be detected by fluorescence in situ hybridization 
analyses and/or array-based genomic copy number 
analyses (Hallor et al., 2009). 
 
Partial karyotype with a t(1;10)(p22;q24) and rearrangement of 3p. 
 
Fluorescence in situ hybridization, using probes flanking the TGFBR3 and MGEA5 genes, respectively, can be used to detect the 
t(1;10)(p22;q24). A normal chromosome 10 show signals from probes located on either side of MGEA5 (labeled in red and yellow). On 
the der(10)t(1;10) the proximal probe (yellow) is detected while the more distal probe (red) is deleted. 






Atlas Genet Cytogenet Oncol Haematol. 2012; 16(7)  511 
 
DNA copy number analysis of a MIFS using array comparative genomic hybridization. A genome-wide copy number profile displays 
tumor/reference log2 ratios across the genome (top). Individual chromosomes are separated by vertical bars and chromosome 3 is 
labeled in yellow. The profile shows amplification of material from chromosome 3 and a few additional aberrations. Enlarged view of 
chromosome 3 shows two separate amplicons, the more proximal of these contains the VGLL3 gene (bottom). 
 
Genes involved and proteins 
Note 
The breaks in chromosomes 1 and 10 seem to occur in, 
or close to, the genes TGFBR3 and MGEA5, 
respectively, and the translocation juxtaposes FGF8 in 
chromosome 10 with TGFBR3 in chromosome 1 
(Hallor et al., 2009).  
FGF8 is highly expressed, likely as a result of the
rearrangement, in tumors affected by the translocati n. 
Ring and giant marker 
chromosomes in MIFS contain amplified material from 
chromosome 3.  
The core amplicon harbors the gene VGLL3, which is 
also highly expressed in affected tumors (Hallor et al., 
2009).  
This abnormality is, however, not specific for 
MIFS/HFLT and have been found in additional 
sarcomas as well as other malignancies (Hélias-
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Fluorescence in situ hybridization analyses suggest that TGFBR3 is translocated from chromosome 1 and positioned in opposite 
direction next to the MGEA5 gene on the der(10)t(1;10) (Hallor et al., 2009). 
 
Note 
Amplification and high expression of VGLL3 in 
chromosome 3 is found in MIFS and HFLT as well as 
other sarcomas. 
DNA / RNA 
VGLL3 is a protein coding gene located at position 
86987119-87040269 in chromosome 3 
(http://www.ensembl.org; human assembly GRCh37). 
There are three transcript variants of this gene. The 
most extensive variant (transcript variant 1) comprises 
10400 base pairs and consists of 4 coding exons. 
Protein 
VGLL3 encodes the protein vestigial like 3 
(Drosophila). Translation of VGLL3 transcript variant 
1 results in a 326 amino acid protein. There is not much 
known about the function of this protein. However, it is 
believed that mammlian vestigal like proteins could be 
involved in regulating members of the TEAD 
transcription factor family (Vaudin et al., 1999; Maeda 





The translocation between chromosomes 1 and 10 
juxtaposes FGF8 in chromosome 10 with TGFBR3 in 
chromosome 1. In tumors affected by the translocatin, 
FGF8 is highly expressed. 
DNA / RNA 
FGF8 is a highly conserved gene located at position 
103530081-103535827 in chromosome 10 
(http://www.ensembl.org; human assembly GRCh37). 
There are six transcript variants of this gene and the 
alternating splicing results in products of 4-6 exons, 
which in turn encode proteins of 204-244 amino acids. 
The expression of FGF8 is controlled by several 
regulatory sequences located both upstream and 
downstream of the gene (Beermann et al., 2006; Inoue 
et al., 2006). 
Protein 
Fibroblast growth factor 8 belongs to the large family 
of fibroblast growth factors. Members of this family are 
secreted molecules which by activating their receptors 
are involved in a variety of biological processes (Thisse 
and Thisse et al., 2005). FGF8 is transcriptionally si ent 
in most normal adult tissues. However, upregulation of 
this gene has been associated with tumor growth and 
has been identified in carcinomas of the breast, 
prostate, and ovary, as well as in synovial sarcoma 
(Tanaka et al., 1998; Ishibe et al., 2005; Mattila et al., 
2007). 




The t(1;10) juxtaposes FGF8 in chromosome 10 with 
TGFBR3 in chromosome 1 and the rearrangement is 
associated with high expression of FGF8 (Hallor et al., 
2009). 
Description 
The translocation does not result in a conventional 
fusion gene. The functional outcome of the recurrent 
aberration seems to be high expression of the gene 
FGF8 (Hallor et al., 2009). The consistent involvement 
of TGFBR3, but lack of fusion transcripts, suggest that 
regulatory sequences in TGFBR3 are crucial for 
malignant transformation. 
Transcript 
Rearrangements of TGFBR3 and MGEA5. 
Detection 
Fluorescence in situ hybridization analysis using probes 
flanking the TGFBR3 and MGEA5 genes can be 
applied as a molecular test for detecting rearrangements 
of the genes (Antonescu et al., 2011). 
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